RxDoctor Payments Data

Natale Falanga, MD

Internal Medicine · East Stroudsburg, PANPI 1962402479

Payments from drug & device makers

$14,207in general payments, 2019–2025

Across 701 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Boehringer Ingelheim$2K
  • AstraZeneca$1K
  • GSK$1K
  • E.r. Squibb & Sons, L.L.C.$838
  • Pfizer$680
  • plus $6K from 39 others

What the payments were for

  • Consulting fees$1001%
  • Food & beverage$13,88898%
  • Education$2202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,207 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$191,304
Medicare patients
502
Services billed
2,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$88,195
JardianceEmpagliflozin81$79,448
OzempicSemaglutide55$72,882
FarxigaDapagliflozin Propanediol46$55,223
JanuviaSitagliptin Phosphate34$45,231
XareltoRivaroxaban37$44,054
RybelsusSemaglutide19$28,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$24,137
TrulicityDulaglutide16$21,343
OxycontinOxycodone Hcl14$20,292
WegovySemaglutide14$18,581
LinzessLinaclotide21$13,192
VascepaIcosapent Ethyl24$12,450
Breo ElliptaFluticasone/Vilanterol13$8,282
BelsomraSuvorexant13$6,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$2,281$119,72788 claims
PfizerEliquis, Paxlovid$680$90,930129 claims
Boehringer IngelheimJardiance$1,585$79,44881 claims
AstraZenecaFarxiga$1,428$55,22346 claims
MerckJanuvia, Belsomra$650$52,03947 claims
Johnson & JohnsonXarelto$627$44,05437 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$1,150$35,55357 claims
Lilly USA, LLCTrulicity$311$21,34316 claims
AbbVieLinzess, Fetzima$416$19,10833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in East Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →